* Oramed Pharmaceuticals Inc reported quarterly adjusted earnings of 26 cents per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of -3 cents. The mean expectation of two analysts for the quarter was for earnings of one cent per share. Wall Street expected results to range from -2 cents to 4 cents per share.
* Reported revenue was zero; analysts expected $250.00 thousand.
* Oramed Pharmaceuticals Inc's reported EPS for the quarter was 26 cents.
* The company reported quarterly net income of $10.75 million.
* Oramed Pharmaceuticals Inc shares had fallen by 12.8% this quarter and lost 3.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 150% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"
Wall Street's median 12-month price target for Oramed Pharmaceuticals Inc is $3.25 This summary was machine generated from LSEG data August 15 at 06:51 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 0.01 0.26 Beat
Mar. 31 2024 0.02 0.04 Beat
Dec. 31 2023 -0.12 0.33 Beat
Sep. 30 2023 -0.08 -0.08 Met
Comments